Galectin Therapeutics Inc. ( GALT) - Key Metrics
GALT Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$0.14 | -$0.04 | -$0.04 |
| 2026Q1 | $0 | -$0.08 | -$0.06 | -$0.06 |
| 2025Q4 | $0 | -$0.09 | -$0.09 | -$0.09 |
| 2025Q3 | $0 | -$0.13 | -$0.06 | -$0.06 |
| 2025Q2 | $0 | -$0.12 | -$0.10 | -$0.10 |
GALT Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -8.29 |
| 2026Q1 | -1.21% | -9.06 |
| 2025Q4 | 0% | -13 |
| 2025Q3 | 0% | -8.15 |
| 2025Q2 | 0% | -4.40 |
GALT
Price: $3.62
52 week price:
Earnings Per Share: -0.45 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 205300
Ebitda: -4.4 millionMarket Capitalization: 238.1 million